Featured CMO:   Boehringer Ingelheim

As one of the leading companies for the contract manufacturing of biopharmaceuticals, Boehringer Ingelheim offers the entire production technology chain in development and production at its facilities in Biberach (Germany) and Vienna (Austria). The large scale manufacturing sites deliver biopharmaceutical products like therapeutic proteins, fusion proteins, protein scaffolds, monoclonal antibodies, antibody mimetics and plasmid DNA.

The Biberach site is specialized in highly efficient mammalian cell culture systems with yields well above industry standard. The Austria site offers high-expression in bacteria and yeast with exceptionally high productivities using proprietary systems. In the plasmid DNA manufacturing arena, Boehringer Ingelheim in Austria has set the standard, and supplies early to late-stage clinical trials with gene-therapeutics and DNA vaccines for its international clients.

Our customers benefit from a track record of 15 launched biopharmaceutical products, which have been developed and produced in our state-of the art facilities following our one-stop-shop concept. By designing tailor-made solutions, a collaboration with Boehringer Ingelheim is an attractive strategic option for our world wide partners who want to speed up product development while minimizing investment risk. Our contract development and manufacturing strategy is made up of flexible modules covering the entire process chain from cell line development to fill and finish.